Biotest AG opens sixth plasma collection centre in Czech Republic
- 26 plasma collection centres in Europe to ensure long-term plasma supply
Dreieich, 23 August 2021. Biotest has received the operating license for its sixth plasma collection centre in Czech Republic from the country's national public health authority SUKL. The centre is located in the historical part of the Moravian capital Brno near the main railway station.
In the state-of-the-art centre with 15 donor beds, donors can watch TV or use Wi-Fi while donating. The centre is open 6 days a week for 12 hours a day.
Biotest is continuing on its planned path to expand its own donation stations in order to increase its plasma collection capacity and creates 12 new jobs in the Czech Republic. The plasma from the additional centre will be used to support to future growth at the new production facility in Dreieich.
"We are very pleased to open Brno, another state-of-the-art plasma centre in the Czech Republic. A special thank you to all our current and future plasma donors who continue to donate at our centres during the Corona pandemic, making an important contribution to the production of valuable plasma-based medicines. Of course, our thanks also go to our dedicated staff, without whom a continuous donation and supply of plasma would not be possible," underlines Dr. Frank Velte, Vice President Plasma Service Europe GmbH.
The collected plasma is processed exclusively at Biotest AG in Dreieich. Audits conducted regularly in the Czech Republic ensure that the high legal and internal quality requirements are met.
About human blood plasma
Human blood plasma is a raw material used to produce plasma derived products, which are used to treat various illnesses of the immune system, the blood system, as well as in emergency medicine. Biotest ranks as one of the world's sixth largest plasma protein product manufacturing groups. Biotest is one of the world's six largest manufacturers of plasma protein products.
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 1,900 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.
Dr Monika Buttkereit
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com
Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.
23.08.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de